Latest Trading on NASDAQ

Open 77.01
Previous Close 76.66
Today's Range
76.45 78.07
52 Week Range
32.95 90.19
Volume 482.60K
Avg. Volume (Weekly) 499.76K
Bid 66.35
Ask 95.00
Market Cap 4.52M
EPS -7.06
Shares Outstanding 58.16K
YTD High 81.97
Updated October 13, 2020

Arena Pharmaceuticals Inc.

Arena Pharmaceuticals Inc. (“Arena”) develops drugs that selectively target protein receptors of cells. Its research and development efforts are premised under the hypothesis that drugs designed to selectively target these receptors provide more effective and safe treatments.

No data to display.

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.